Pristimerin ameliorates spasmolytic polypeptide-expressing metaplasia by modulating Cdkn1c (p57)-mediated glycolytic reprogramming

Figure 2 Pristimerin alleviates spasmolytic polypeptide-expressing metaplasia-related oxyntic atrophy in mice. A-C: Immunofluorescence and reverse transcription quantitative polymerase chain reaction detection of hydrogen-potassium-adenosine-triphosphatase (parietal cells), gastric intrinsic factor and mist (chief cells) expression in gastric mucosa of high-dose tamoxifen-induced spasmolytic polypeptide-expressing metaplasia mice treated with pristimerin. Scale bar, 20 μm; D: Inhibitory effect of pristimerin on gastric mucosal cell proliferation in mice. Scale bar, 20 μm. ^aP < 0.05; ^bP < 0.01; ^cP < 0.001; ^dP < 0.0001. Values represent the mean ± SD (n = 6). DAPI: 4’,6-diamidino-2-phenylindole; H⁺/K⁺ ATPase: Hydrogen-potassium-adenosine-triphosphatase; GIF: Gastric intrinsic factor; Pri-L: Low-dose pristimerin; Pri-M: Medium-dose pristimerin; Pri-H: High-dose pristimerin; IOD: Integrated optical density.